君实生物与德琪医药达成癌症临床研究合作2月25日,君实生物宣布与德琪医药达成战略合作,双方将共同探索君实生物自主研发的JS207(抗PD-1/VEGF双特异性抗体)与德琪医药的ATG-037(口服CD73小分子抑制剂)在中国大陆肿瘤患者中的联合治疗协同潜力。截图来源:君实生物官微公开资料显示,JS207是君实生物自主研发的重组人源化抗PD-1和VEGF双特异性抗体,在临床前及临床研究中均显示出良好...
Source Link君实生物与德琪医药达成癌症临床研究合作2月25日,君实生物宣布与德琪医药达成战略合作,双方将共同探索君实生物自主研发的JS207(抗PD-1/VEGF双特异性抗体)与德琪医药的ATG-037(口服CD73小分子抑制剂)在中国大陆肿瘤患者中的联合治疗协同潜力。截图来源:君实生物官微公开资料显示,JS207是君实生物自主研发的重组人源化抗PD-1和VEGF双特异性抗体,在临床前及临床研究中均显示出良好...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.